NS 065

Drug Profile

NS 065

Alternative Names: Exon 53 skipping antisense oligonucleotide - Nippon Shinyaku/National Center of Neurology and Psychiatry; Exon 53 skipping DMD therapeutic - Nippon Shinyaku/National Center of Neurology and Psychiatry; NCNP-01; NS-065/NCNP-01; NS065

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Center of Neurology and Psychiatry; Nippon Shinyaku
  • Class Antisense oligonucleotides
  • Mechanism of Action Dystrophin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 06 Jul 2017 NS Pharma initiates enrolment in an extension phase II trial for Duchenne muscular dystrophy (In children) in Canada and USA (NCT03167255)
  • 29 May 2017 NS Pharma plans a phase II trial for Duchenne muscular dystrophy(In children) in Canada and USA (NCT03167255)
  • 01 Feb 2017 NS 065 receives rare paediatric disease designation for Duchenne muscular dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top